Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-high dose dexamethasone in relapsed multiple myeloma
NCT02402725Phase 2Withdrawn
- Sponsor
- Boston Medical Center
- Start
- May 2015
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dexamethasone in multiple myeloma (MM), sponsored by Boston Medical Center. Primary endpoints: Objective Response Rate at 1 year and Change from baseline in M protein component at 1 year. Planned start May 2015; status: withdrawn.
02
Drugs
dexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02402725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402725.